However, no difference in survival was found between ESCC patients in advanced stage with (median survival time: 18 months) and without (median survival time: 16 months) FZD7 overexpression (P=0.3020, Supplementary Figure 2B), indicating that FZD7 might be a potential prognostic marker for early stage of ESCC patients. The gene discussed is FZD7; the disease is esophageal squamous cell carcinoma.